Three Stocks That Might Be Undervalued In September 2024

As global markets grapple with economic slowdown concerns, the S&P 500 Index has experienced its steepest weekly decline in 18 months, driven by fears of a weakening U.S. labor market and seasonal trading patterns. Despite these challenges, certain stocks may present opportunities for investors seeking undervalued assets amidst the turbulence. In this environment, identifying undervalued stocks involves looking for companies with strong fundamentals that are temporarily out of favor or overlooked by the broader market. Here are three stocks that might be undervalued in September 2024.

Top 10 Undervalued Stocks Based On Cash Flows

Name	Current Price	Fair Value (Est)	Discount (Est)
Zhongji Innolight (SZSE:300308)	CN¥115.94	CN¥231.41	49.9%
Ningxia Baofeng Energy Group (SHSE:600989)	CN¥14.45	CN¥28.76	49.8%
Kotobuki Spirits (TSE:2222)	¥1719.00	¥3434.73	50%
Plus Alpha ConsultingLtd (TSE:4071)	¥2087.00	¥4159.01	49.8%
Napatech (OB:NAPA)	NOK32.00	NOK63.99	50%
Informa (LSE:INF)	£8.458	£16.88	49.9%
Shanghai INT Medical Instruments (SEHK:1501)	HK$28.20	HK$56.09	49.7%
EVERTEC (NYSE:EVTC)	US$33.14	US$65.97	49.8%
Hiconics Eco-energy Technology (SZSE:300048)	CN¥4.36	CN¥8.70	49.9%
Vertex Pharmaceuticals (NasdaqGS:VRTX)	US$478.65	US$956.80	50%

Click here to see the full list of 917 stocks from our Undervalued Stocks Based On Cash Flows screener.

We'll examine a selection from our screener results.

Alnylam Pharmaceuticals (NasdaqGS:ALNY)

Overview: Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference, with a market cap of $33.62 billion.

Operations: The company generates $2.34 billion from the discovery, development, and commercialization of RNAi therapeutics.

Estimated Discount To Fair Value: 48.9%

Alnylam Pharmaceuticals ($261.73) appears undervalued, trading at 48.9% below its estimated fair value of $511.94 based on discounted cash flow analysis. Despite recent insider selling and shareholder dilution, the company’s earnings are forecast to grow 65.21% annually, with revenue expected to increase by 19.3% per year—outpacing the US market average of 8.8%. Recent positive results from the HELIOS-B Phase 3 study further bolster its growth prospects as it aims for profitability within three years.

• Our earnings growth report unveils the potential for significant increases in Alnylam Pharmaceuticals' future results.
• Click to explore a detailed breakdown of our findings in Alnylam Pharmaceuticals' balance sheet health report.

Molina Healthcare (NYSE:MOH)

Overview: Molina Healthcare, Inc. provides managed healthcare services to low-income families and individuals under the Medicaid and Medicare programs and through state insurance marketplaces, with a market cap of approximately $20.20 billion.

Operations: The company's revenue segments include Medicaid at $30.03 billion, Medicare at $5.03 billion, and Marketplace at $2.26 billion.

Estimated Discount To Fair Value: 45%

Molina Healthcare ($352.94) is trading at 45% below its estimated fair value of $641.75, suggesting it may be undervalued based on discounted cash flow analysis. The company’s earnings are forecast to grow 16.97% annually, outpacing the US market average of 15.2%. Recent earnings reports show revenue growth from $8.33 billion to $9.88 billion year-over-year for Q2 2024, although net income slightly declined from $309 million to $301 million in the same period.

• Upon reviewing our latest growth report, Molina Healthcare's projected financial performance appears quite optimistic.
• Take a closer look at Molina Healthcare's balance sheet health here in our report.

Zhongji Innolight (SZSE:300308)

Overview: Zhongji Innolight Co., Ltd. researches, develops, produces, and sells optical communication transceiver modules and optical devices in China, with a market cap of CN¥119.31 billion.

Operations: The company's revenue segments include optical communication transceiver modules and optical devices in China.

Estimated Discount To Fair Value: 49.9%

Zhongji Innolight (CN¥115.94) is trading at 49.9% below its estimated fair value of CN¥231.41, indicating significant undervaluation based on discounted cash flow analysis. The company reported a substantial increase in half-year revenue to CN¥10.80 billion from CN¥4 billion year-over-year, with net income rising to CN¥2.36 billion from CN¥613 million. Earnings and revenue are forecast to grow annually by 31.8% and 32.4%, respectively, outpacing market averages significantly.

• Our comprehensive growth report raises the possibility that Zhongji Innolight is poised for substantial financial growth.
• Dive into the specifics of Zhongji Innolight here with our thorough financial health report.

Taking Advantage

• Embark on your investment journey to our 917 Undervalued Stocks Based On Cash Flows selection here.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com